Document is current

Article History

Received: 28 March 2025

Accepted: 16 June 2025

First Online: 19 July 2025

Declarations

:

: The NHS Health Research Authority granted ethical approval of the study on 11 May 2021 (IRAS ID: 292980). Patients’ data were pseudo-anonymised before collection and no patient could be identified at any stage of the study. As this was a retrospective chart review, a waiver for the collection of informed consent was granted by the NHS Health Research Authority ahead of data collection. This study adhered to the principles outlined in the UK Policy Framework for Health and Social Care Research, the Declaration of Helsinki, and all relevant institutional guidelines and regulations. All procedures involving human data complied with these standards.

: Not applicable.

: WF, RJ and WB are employees, stockholders and shareholders of Eli Lilly and Company Ltd., and GH is an employee of Adelphi Real World. JK has participated in advisory boards for: AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, Exact Science, Gilead, Novartis, Prosigna, Roche and SeaGen, and as an invited speaker for AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Prosigna, Roche and SeaGen. CP has received grants and research support to the institution from Daiichi Sankyo, Exact Sciences, Gilead, Pfizer, SeaGen, participated in advisory boards for Daiichi Sankyo, Eli Lilly, Exact Sciences, Gilead, Novartis, Pfizer, Roche, SeaGen and received travel honoraria from Gilead, Novartis and Roche. MN has received honoraria to be an invited speaker for AstraZeneca, Eli Lilly, MSD, Novartis, Pfizer, Roche and SeaGen.